News on NGS technologies, RNA-seq, clinical sequencing, & sample prep in genetics, genomics, and molecular diagnostics.
The firm posted total software-related revenues of $18.6 million, up 1 percent from $18.4 million in Q4 2019.
Adaptive Cofounder and Chief Scientific Officer Harlan Robins compared the launch of the test to the unveiling of the Tesla Roadster electric sports car.
The firm expects to release an expanded liquid biopsy panel this year to help pharmaceutical partners perform blood-based biomarker discovery work.
The immune cell sequencing company beat Wall Street estimates on the top line, but missed on the bottom line for both Q4 and full-year 2020.
The partners will develop a test to identify women most likely to benefit from VGX-3100, Inovio's immunotherapy to treat HPV-associated advanced cervical dysplasia.
